David lagares
Chief Executive Officer, President & Founder Zenon Biotech
Seminars
Wednesday 2nd December 2026
Targeting Mechanobiology to Disrupt Self-Sustaining Fibrosis: A New Path to Disease Reversal
4:45 pm
- Understanding how matrix stiffness and mechanical signaling create self-sustaining fibrotic pathways across organs, independent of the initiating injury or inflammation
- Identifying and validating druggable nodes across the mechanotransduction pathway, from focal-adhesion mechanosensors to downstream transcriptional effectors
- Applying emerging discovery platforms and translational models to develop selective mechanobiology-targeted therapies that disrupt fibrotic tissue while preserving normal homeostasis and repair
Thursday 3rd December 2026
Fireside Chat: Moving Beyond Slowing Fibrosis to Define the Biology, Data & Trial Designs Needed to Stop or Reverse Disease to Deliver Meaningful Patient Benefit
10:00 am
- Reflecting on the discoveries that have enabled antifibrotic therapies to slow disease progression, and debating whether these same insights are sufficient to guide therapies that stop or reverse fibrosis
- Defining what true fibrosis regression means, including ECM remodeling, fibrinolysis, fibroblast deactivation, restored tissue architecture and functional recovery
- Determining whether different cell types, molecular mechanisms, datasets, biomarkers, and clinical trial designs are needed to distinguish therapies that slow progression from those that actively reverse fibrotic disease
